DK1468686T3 - S-methyl-dihydro-ziprasidon til behandling af psykiatriske lidelser - Google Patents

S-methyl-dihydro-ziprasidon til behandling af psykiatriske lidelser

Info

Publication number
DK1468686T3
DK1468686T3 DK04013380T DK04013380T DK1468686T3 DK 1468686 T3 DK1468686 T3 DK 1468686T3 DK 04013380 T DK04013380 T DK 04013380T DK 04013380 T DK04013380 T DK 04013380T DK 1468686 T3 DK1468686 T3 DK 1468686T3
Authority
DK
Denmark
Prior art keywords
ziprasidone
dihydro
methyl
treatment
psychiatric disorders
Prior art date
Application number
DK04013380T
Other languages
Danish (da)
English (en)
Inventor
Chandra Prakash
Teresa Annette Smolarek
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26903852&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1468686(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Application granted granted Critical
Publication of DK1468686T3 publication Critical patent/DK1468686T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicinal Preparation (AREA)
DK04013380T 2000-06-02 2001-05-28 S-methyl-dihydro-ziprasidon til behandling af psykiatriske lidelser DK1468686T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20913600P 2000-06-02 2000-06-02
US21217200P 2000-06-16 2000-06-16
PCT/IB2001/000933 WO2001091756A2 (en) 2000-06-02 2001-05-28 S-methyl-dihydro-ziprasidone for treatment of psychiatric and ocular disorders

Publications (1)

Publication Number Publication Date
DK1468686T3 true DK1468686T3 (da) 2007-03-12

Family

ID=26903852

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04013380T DK1468686T3 (da) 2000-06-02 2001-05-28 S-methyl-dihydro-ziprasidon til behandling af psykiatriske lidelser

Country Status (44)

Country Link
US (1) US20060287336A1 (ja)
EP (3) EP1468686B1 (ja)
JP (2) JP2003534381A (ja)
KR (1) KR20030007824A (ja)
CN (1) CN1431901A (ja)
AP (2) AP1831A (ja)
AR (1) AR028937A1 (ja)
AT (3) ATE345818T1 (ja)
AU (1) AU2001258690A1 (ja)
BG (1) BG107267A (ja)
BR (1) BR0111271A (ja)
CA (1) CA2410618A1 (ja)
CY (1) CY1105992T1 (ja)
CZ (1) CZ20023860A3 (ja)
DE (3) DE60124791T2 (ja)
DK (1) DK1468686T3 (ja)
DO (1) DOP2001000181A (ja)
EA (1) EA007068B1 (ja)
EC (1) ECSP024369A (ja)
EE (1) EE200200670A (ja)
ES (1) ES2277170T3 (ja)
GE (1) GEP20053512B (ja)
HN (1) HN2001000119A (ja)
HR (1) HRP20020953A2 (ja)
HU (1) HUP0301747A2 (ja)
IL (2) IL152782A0 (ja)
IS (1) IS6619A (ja)
MA (1) MA26908A1 (ja)
MX (1) MXPA02011862A (ja)
NO (1) NO325077B1 (ja)
NZ (1) NZ551012A (ja)
OA (1) OA12267A (ja)
PA (1) PA8518301A1 (ja)
PE (1) PE20011329A1 (ja)
PL (1) PL365576A1 (ja)
PT (2) PT1468686E (ja)
SI (1) SI1468686T1 (ja)
SK (1) SK16622002A3 (ja)
SV (1) SV2002000473A (ja)
UA (1) UA79425C2 (ja)
UY (1) UY26742A1 (ja)
WO (1) WO2001091756A2 (ja)
YU (1) YU90702A (ja)
ZA (1) ZA200209665B (ja)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004054487A2 (en) 2002-12-13 2004-07-01 Regents Of The University Of Minnesota Scleral depressor
WO2005040160A2 (en) 2003-10-24 2005-05-06 Teva Pharmaceutical Industries Ltd. Processes for preparation of ziprasidone
ES2250001B1 (es) * 2004-09-29 2007-06-01 Medichem, S.A. Proceso para la purificacion de ziprasidona.
JP2012174228A (ja) * 2011-02-24 2012-09-10 Kyocera Corp プログラム保護装置および通信装置
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神分裂病を処置するための方法および組成物
US9981041B2 (en) * 2016-08-23 2018-05-29 Ira Jason Salzman Ophthalmic lubricating spray

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE236902T1 (de) * 1996-05-07 2003-04-15 Pfizer Mesylat des trihydrats des 5-(2-(4-(1,2- benzothiazol-3-yl)-1-piperazinyl)ethyl)-6-chlor 1,3-dihydro-2(1h)-indol-2-ons (=ziprasidon), seine herstellung und seine anwendung als dopamin d2 antagonist
TW491847B (en) * 1996-05-07 2002-06-21 Pfizer Mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2h-indol-2-one
EP0985414B1 (en) * 1998-05-26 2003-08-27 Pfizer Products Inc. Medicament for the treatment of glaucoma and ischemic retinopathy
AU4062900A (en) * 1999-04-06 2000-10-23 Sepracor, Inc. Methods and compositions for the treatment of neuroleptic and related disorders using ziprasidone metabolites

Also Published As

Publication number Publication date
ATE345818T1 (de) 2006-12-15
PL365576A1 (en) 2005-01-10
EE200200670A (et) 2004-08-16
DE60133596D1 (de) 2008-05-21
HUP0301747A2 (hu) 2003-09-29
EP1698338A3 (en) 2006-09-20
EP1468686A3 (en) 2004-12-01
EP1468686A2 (en) 2004-10-20
CY1105992T1 (el) 2011-04-06
EP1698338B1 (en) 2008-04-09
MA26908A1 (fr) 2004-12-20
KR20030007824A (ko) 2003-01-23
PT1698338E (pt) 2008-06-03
ZA200209665B (en) 2003-11-28
JP2008056700A (ja) 2008-03-13
SV2002000473A (es) 2002-10-24
ATE391507T1 (de) 2008-04-15
AU2001258690A1 (en) 2001-12-11
EP1286672B1 (en) 2006-10-25
MXPA02011862A (es) 2003-04-10
EA007068B1 (ru) 2006-06-30
NO325077B1 (no) 2008-01-28
PT1468686E (pt) 2007-01-31
EP1286672A2 (en) 2003-03-05
NO20025760D0 (no) 2002-11-29
AP1831A (en) 2008-02-26
HRP20020953A2 (en) 2005-02-28
ECSP024369A (es) 2003-02-06
OA12267A (en) 2004-01-20
IS6619A (is) 2002-11-14
AR028937A1 (es) 2003-05-28
UA79425C2 (en) 2007-06-25
SK16622002A3 (sk) 2004-07-07
DE60124791T2 (de) 2007-09-13
BG107267A (bg) 2003-06-30
AP1747A (en) 2007-05-31
WO2001091756A3 (en) 2002-09-26
IL152782A0 (en) 2003-06-24
YU90702A (sh) 2005-11-28
PE20011329A1 (es) 2002-01-15
GEP20053512B (en) 2005-05-10
CZ20023860A3 (cs) 2004-01-14
BR0111271A (pt) 2003-06-10
IL152782A (en) 2007-10-31
DOP2001000181A (es) 2002-04-15
EP1698338A2 (en) 2006-09-06
US20060287336A1 (en) 2006-12-21
WO2001091756A2 (en) 2001-12-06
SI1468686T1 (sl) 2007-04-30
EA200201168A1 (ru) 2003-06-26
EP1468686B1 (en) 2006-11-22
JP2003534381A (ja) 2003-11-18
CA2410618A1 (en) 2001-12-06
UY26742A1 (es) 2001-12-28
AP2005003272A0 (en) 2005-03-31
CN1431901A (zh) 2003-07-23
DE60124093D1 (de) 2006-12-07
ES2277170T3 (es) 2007-07-01
DE60124791D1 (de) 2007-01-04
PA8518301A1 (es) 2002-09-17
NZ551012A (en) 2008-04-30
HN2001000119A (es) 2001-09-11
NO20025760L (no) 2003-01-15
ATE343387T1 (de) 2006-11-15

Similar Documents

Publication Publication Date Title
DK1343773T3 (da) Thiazolderivater til behandling af PPAR-beslægtede forstyrrelser
DK1259512T3 (da) Pteridinforbindelser til behandling af psoreasis
DK0967214T3 (da) Intranasale formuleringer til behandling af seksuelle forstyrrelser
DK1063990T3 (da) Anvendelse af Biochanin-beriget ekstrakt til behandling af östrogen-associerede lidelser
DK1474416T3 (da) Dihydrobenzodiazepin-2-on-derivater til behandlingen af neurologiske lidelser
IS7099A (is) Efnasambönd til að meðhöndla bólgutruflanir
DK1296935T3 (da) Fremgangsmåde til fremstilling af substituerede octanoylamider
DK1147083T3 (da) Arylpiperazinyl-cyclohexylindolderivater til behandling af depression
DK1144395T3 (da) 2-amino-benzoxazinon-derivater til behandling af fedme
DK1562932T3 (da) 4 tetrazolyl-4-phenylpiperidinderivater til behandling af smerter
DK1448205T3 (da) Kombinationer til behandling af immunoinflammatoriske sygdomme
DK1282616T3 (da) Hydroxyphenylpiperidin-4-ylidenmethylbenzamidderivater til behandling af smerter
DK1392318T3 (da) 15-keto-prostaglandiner til behandling af lægemiddelinduceret forstoppelse
DK1380121T3 (da) Fremgangsmåde til fremstilling af oxazolidinoner
DK1324970T3 (da) Retinoider til behandling af emfysem
DK2189162T3 (da) Fremgangsmåder til behandling af cellulære proliferative forstyrrelser
DK1344526T3 (da) Midler til forebyggelse/behandling af inflammatoriske luftvejslidelser
DK1345598T3 (da) Anvendelsen af rosiglitazon til behandling af psykiatriske lidelser
DK1326628T3 (da) Kemokinmutanter til behandling af dissemineret sklerose
DK1350521T3 (da) Immunoterapeutiske kombinationer til behandling af tumorer
DK1257278T3 (da) Anvendelse af mirtazapin til behandling af sövnforstyrrelser
DK1268482T3 (da) Pyranoindoler til behandling af glaukom
DK1468686T3 (da) S-methyl-dihydro-ziprasidon til behandling af psykiatriske lidelser
DK1121356T3 (da) 3-tetrahydropyridin-4-yl-indoler til behandling af psykotiske lidelser
DK1468996T3 (da) Indolderivater til behandling af CNS-sygdomme